A neutralizing monoclonal antibody targeting the acid-sensitive region in chikungunya virus E2 protects from disease
about
Early Events in Chikungunya Virus Infection-From Virus Cell Binding to Membrane FusionExposure of epitope residues on the outer face of the chikungunya virus envelope trimer determines antibody neutralizing efficacyChikungunya viruses that escape monoclonal antibody therapy are clinically attenuated, stable, and not purified in mosquitoesMultiple immune factors are involved in controlling acute and chronic chikungunya virus infectionDevelopment of Neutralization Assay Using an eGFP Chikungunya VirusChikungunya vaccines in developmentA potent neutralizing IgM mAb targeting the N218 epitope on E2 protein protects against Chikungunya virus pathogenesisTherapy with CTLA4-Ig and an antiviral monoclonal antibody controls chikungunya virus arthritisRNA-Seq analysis of chikungunya virus infection and identification of granzyme A as a major promoter of arthritic inflammationChikungunya virus: epidemiology, replication, disease mechanisms, and prospective intervention strategies.Therapeutic administration of a recombinant human monoclonal antibody reduces the severity of chikungunya virus disease in rhesus macaques.Development of a Novel Virus-Like Particle Vaccine Platform That Mimics the Immature Form of Alphavirus.Unique epitopes recognized by antibodies induced in Chikungunya virus-infected non-human primates: implications for the study of immunopathology and vaccine development.Isolation and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus.The neutralizing role of IgM during early Chikungunya virus infectionCryo-EM structures elucidate neutralizing mechanisms of anti-chikungunya human monoclonal antibodies with therapeutic activityNeutralizing Monoclonal Antibodies Block Chikungunya Virus Entry and Release by Targeting an Epitope Critical to Viral Pathogenesis.A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection.Attenuated and vectored vaccines protect nonhuman primates against Chikungunya virus.Immune-Mediated Protection and Pathogenesis of Chikungunya Virus.Chikungunya Virus.Age has a role in driving host immunopathological response to alphavirus infection.Monoclonal Antibodies as Prophylactic and Therapeutic Agents Against Chikungunya Virus.Chikungunya: vaccines and therapeutics.Strategies Using Bio-Layer Interferometry Biosensor Technology for Vaccine Research and Development.Probing the antigenicity of hepatitis C virus envelope glycoprotein complex by high-throughput mutagenesis.Vaccine and Therapeutic Options To Control Chikungunya Virus.Cellular and Molecular Immune Response to Chikungunya Virus InfectionMxra8 is a receptor for multiple arthritogenic alphaviruses
P2860
Q24701760-5DF64FC7-5DC5-471B-BD08-425B9AA8BC3AQ24701766-C4EE11D8-A3BA-4AE5-B41F-D493DB2B6F1AQ24701786-9A6C1CEB-FC4D-4E24-9618-AF0B8A72827AQ24701792-4DD2401B-2F36-411B-A16D-F40C2615EBD6Q26314416-F7323FA0-33D6-4D89-910B-4EF24FEAE4E6Q26700081-BEA92D4F-2582-4889-99D3-34F042A4922DQ26700129-EA2A2A4B-9A31-4729-86F9-AEE94BF0C3ADQ28656412-FF930263-7C7E-4FE9-9BC6-36DE4A41564BQ28804081-C2868ECC-638D-43C8-AA80-A3D00905768FQ30235512-0F71BF05-6614-4155-B3F9-AFB7284AB837Q33853893-C91CF344-5257-4969-9F80-5CEEF0A0B211Q33876183-4CA207EC-CC22-462E-9983-0303CE18D208Q35155037-F7145EEE-600D-4C51-9747-FD54121E075AQ35850197-ACB2169E-1FA7-4FDE-B499-B16615A9107FQ36275851-AC215570-FCC9-48C8-9ABB-B631BAE1DE4AQ36300209-09BF8A67-1112-4648-86DD-4593EF264236Q36483436-3EA4EF50-8DC0-4B02-AF73-BBD9FF0600B7Q37643733-26F6DCD6-A65C-4E0E-9595-976663C6AF36Q37711813-5856C4A3-AF44-4D86-B077-7CF55C766890Q39013750-3E05C06B-AA67-498C-939F-812FD81FD3B0Q39273197-BA49B84B-4406-41DD-A734-090DB5D6DEB1Q39458858-701724C8-6C0B-4E8B-A216-6426CEC5D045Q40077669-CCF68312-AAD4-407A-A9FE-DCAC8C1784BDQ47098677-08CB63FF-9C4B-42CE-A743-CECAD9E829DDQ47171892-86888C72-D7F5-4BF8-A7B3-7714720CCE32Q47238536-6B167A0A-5593-4815-9DBD-B15A8A15B830Q47566099-8920B01D-92C4-445A-965B-90F811119705Q58575620-21F350CE-6B6E-4876-9B20-91ADFE76170DQ59059482-93F441E5-A014-4C9B-A3EF-D131DA0D824E
P2860
A neutralizing monoclonal antibody targeting the acid-sensitive region in chikungunya virus E2 protects from disease
description
2013 nî lūn-bûn
@nan
2013 թուականին հրատարակուած գիտական յօդուած
@hyw
2013 թվականին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
A neutralizing monoclonal anti ...... virus E2 protects from disease
@ast
A neutralizing monoclonal anti ...... virus E2 protects from disease
@en
A neutralizing monoclonal anti ...... virus E2 protects from disease
@nl
type
label
A neutralizing monoclonal anti ...... virus E2 protects from disease
@ast
A neutralizing monoclonal anti ...... virus E2 protects from disease
@en
A neutralizing monoclonal anti ...... virus E2 protects from disease
@nl
prefLabel
A neutralizing monoclonal anti ...... virus E2 protects from disease
@ast
A neutralizing monoclonal anti ...... virus E2 protects from disease
@en
A neutralizing monoclonal anti ...... virus E2 protects from disease
@nl
P2093
P2860
P50
P921
P3181
P1476
A neutralizing monoclonal anti ...... virus E2 protects from disease
@en
P2093
Beatriz Salvador
Benjamin J Doranz
David Avram Sanders
David F Tucker
Giada Rossini
Joseph B Rucker
Joy Gardner
Kimberly-Anne Mattia
Kristen M Kahle
P2860
P3181
P356
10.1371/JOURNAL.PNTD.0002423
P407
P5008
P577
2013-01-01T00:00:00Z